|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/30/22 Nymox Pharmaceutical Corp. 20-F 12/31/21 106:6M Pubco Reporting … Inc/FA |
Document/Exhibit Description Pages Size
1: 20-F Annual or Annual-Transition Report by a Foreign HTML 1.05M
Non-Canadian Issuer
4: EX-13.A Annual or Quarterly Report to Security Holders HTML 24K
5: EX-13.B Annual or Quarterly Report to Security Holders HTML 24K
2: EX-12.A Statement re: the Computation of Ratios HTML 29K
3: EX-12.B Statement re: the Computation of Ratios HTML 28K
11: R1 Cover HTML 96K
12: R2 Consolidated Statements of Comprehensive Loss HTML 67K
13: R3 Consolidated Statements of Financial Position HTML 77K
14: R4 Consolidated Statements of Financial Position HTML 26K
(Parenthetical)
15: R5 Consolidated Statements of Cash Flow HTML 76K
16: R6 Consolidated Statements of Changes in Equity HTML 51K
17: R7 Business Activities and Basis of Presentation HTML 31K
18: R8 Going Concern Considerations HTML 28K
19: R9 Significant Estimates HTML 26K
20: R10 Significant Accounting Policies HTML 66K
21: R11 New Accounting Standards and Interpretations HTML 32K
22: R12 Property and Equipment HTML 79K
23: R13 Intangible Assets HTML 26K
24: R14 Accounts Payable and Accrued Liabilities HTML 37K
25: R15 Operating Leases and Commitments HTML 58K
26: R16 Share Capital HTML 39K
27: R17 Stock Options HTML 61K
28: R18 Share Based Compensation HTML 34K
29: R19 Warrants HTML 53K
30: R20 Income Taxes HTML 69K
31: R21 Earnings Per Share HTML 33K
32: R22 Financial Instruments Fair Value Disclosures HTML 27K
33: R23 Finance Income and Finance Costs HTML 39K
34: R24 Segment Disclosures HTML 39K
35: R25 Concentrations HTML 32K
36: R26 Related Party Transactions HTML 37K
37: R27 Research and Development Expenses HTML 37K
38: R28 Personnel Expenses HTML 36K
39: R29 Capital Disclosures and Financial Risk HTML 27K
40: R30 Foreign Exchange Risk HTML 27K
41: R31 Credit Risk HTML 27K
42: R32 Interest Rate Risk HTML 27K
43: R33 Liquidity Risk HTML 33K
44: R34 Subsequent Events HTML 29K
45: R35 Significant Accounting Policies (Policies) HTML 94K
46: R36 Significant Accounting Policies (Tables) HTML 27K
47: R37 New Accounting Standards and Interpretations HTML 29K
(Tables)
48: R38 Property and Equipment (Tables) HTML 77K
49: R39 Accounts Payable and Accrued Liabilities (Tables) HTML 35K
50: R40 Operating Leases and Commitments (Tables) HTML 54K
51: R41 Share Capital (Tables) HTML 35K
52: R42 Stock Options (Tables) HTML 60K
53: R43 Share Based Compensation (Tables) HTML 31K
54: R44 Warrants (Tables) HTML 50K
55: R45 Income Taxes (Tables) HTML 68K
56: R46 Earnings Per Share (Tables) HTML 32K
57: R47 Finance Income and Finance Costs (Tables) HTML 37K
58: R48 Segment Disclosures (Tables) HTML 37K
59: R49 Concentrations (Tables) HTML 30K
60: R50 Related Party Transactions (Tables) HTML 32K
61: R51 Research and Development Expenses (Tables) HTML 35K
62: R52 Personnel Expenses (Tables) HTML 33K
63: R53 Liquidity Risk (Tables) HTML 30K
64: R54 Significant Accounting Policies (Details) HTML 32K
65: R55 Significant Accounting Policies (Details HTML 30K
Narrative)
66: R56 Property and Equipment (Details) HTML 54K
67: R57 Property and Equipment (Details Narrative) HTML 27K
68: R58 Intangible Assets (Details Narrative) HTML 30K
69: R59 Accounts Payable and Accrued Liabilities (Details) HTML 32K
70: R60 Interest Rate Risk (Details Narrative) HTML 25K
71: R61 Credit Risk (Details Narrative) HTML 25K
72: R62 Foreign Exchange Risk (Details Narrative) HTML 25K
73: R63 Capital Disclosures and Financial Risk (Details HTML 36K
Narrative)
74: R64 Operating Leases and Commitment (Details) HTML 31K
75: R65 Operating Leases and Commitment (Details 1) HTML 35K
76: R66 Operating Leases and Commitment (Details HTML 41K
Narrative)
77: R67 Operating leases and other commitment (Details HTML 34K
Narrative)
78: R68 Share Capital (Details) HTML 38K
79: R69 Share capital (Details Narrative) HTML 36K
80: R70 Stock Options (Details) HTML 49K
81: R71 Stock Options (Details 1) HTML 43K
82: R72 Stock Options (Details Narrative) HTML 28K
83: R73 Share Based Compensation (Details) HTML 33K
84: R74 Share Based Compensation (Details Narrative) HTML 40K
85: R75 Warrants (Details) HTML 35K
86: R76 Warrants (Details Narrative) HTML 33K
87: R77 Income Taxes (Details) HTML 37K
88: R78 Income Taxes (Details 1) HTML 28K
89: R79 Income Taxes (Details 2) HTML 83K
90: R80 Income Taxes (Details Narrative) HTML 26K
91: R81 Earnings Per Share (Details) HTML 28K
92: R82 Finance Income and Finance Costs (Details) HTML 39K
93: R83 Segment Disclosures (Details) HTML 40K
94: R84 Concentrations (Details) HTML 35K
95: R85 Related Party Transactions (Details) HTML 34K
96: R86 Related Party Transactions (Details Narrative) HTML 36K
97: R87 Research and Development Expenses (Details) HTML 38K
98: R88 Personnel Expenses (Details) HTML 32K
99: R89 Personnel Expenses (Details Narrative) HTML 30K
100: R90 Liquidity Risk (Details) HTML 33K
101: R91 Subsequent Events (Details Narrative) HTML 46K
104: XML IDEA XML File -- Filing Summary XML 193K
102: XML XBRL Instance -- nymox_20f_htm XML 1.53M
103: EXCEL IDEA Workbook of Financial Reports XLSX 111K
8: EX-101.CAL XBRL Calculations -- nymox-20211231_cal XML 149K
10: EX-101.DEF XBRL Definitions -- nymox-20211231_def XML 439K
7: EX-101.LAB XBRL Labels -- nymox-20211231_lab XML 853K
9: EX-101.PRE XBRL Presentations -- nymox-20211231_pre XML 714K
6: EX-101.SCH XBRL Schema -- nymox-20211231 XSD 308K
105: JSON XBRL Instance as JSON Data -- MetaLinks 280± 340K
106: ZIP XBRL Zipped Folder -- 0001640334-22-000622-xbrl Zip 207K
EXHIBIT 12 (a)
CERTIFICATION
I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, certify that:
| 1. | I have reviewed this annual report for the period ended December 31, 2021 of Nymox Pharmaceutical Corporation; |
|
| |
| 2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
|
| |
| 3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report; |
|
| |
| 4. | The company’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a – 15(e) and 15d – 15(e)), and internal control over financial reporting (as defined in the Exchange Act Rules 13a–15(f) and 15d–15(f)) for the company based on the COSO 1992 framework and we have: |
|
| a) | designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
|
| ||
|
| b) | designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with international financial reporting standards; |
|
| ||
|
| c) | evaluated the effectiveness of the company’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
|
| ||
|
| d) | disclosed in this report any change in the company’s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company’s internal control over financial reporting; and |
| 5. |
The company’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company’s auditors and the audit committee of the company’s board of directors (or persons performing the equivalent function): |
|
| a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company’s ability to record, process, summarize and report financial information; and |
|
| ||
|
| b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the company’s internal control over financial reporting. |
| Date: March 30, 2022 | ||
|
|
| |
| By: | ||
|
| ||
|
| President and Chief Executive Officer | |
|
| Nymox Pharmaceutical Corporation | |
| This ‘20-F’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 3/30/22 | None on these Dates | ||
| For Period end: | 12/31/21 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/31/16 Nymox Pharmaceutical Corp. 20-F 12/31/15 8:1.2M e3 Fil… Computershare/FA 6/03/11 Nymox Pharmaceutical Corp. 20-F/A 12/31/10 7:474K e3 Fil… Computershare/FA 6/30/04 Nymox Pharmaceutical Corp. 20-F 12/31/03 7:1.1M Foley & Lardner/FA 6/27/02 Nymox Pharmaceutical Corp. 20-F 12/31/01 2:246K Foley & Lardner/FA |